Skip to content
Biodatica
Start free

Nanjing IASO Biotechnology Co., Ltd.

Shanghai

OncologyPhase I
Compare Sign in to watch

What changed

Phase I trial registered: A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

May 2025Trial registeredMay 20, 2025Source filing (opens the source filing in a new tab)

Momentum

42no change

Momentum 42 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE1 registered

    Mar 30, 2023

    Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia · RECRUITING · sponsor: Nanjing IASO Biotechnology Co., Ltd. · A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

    ClinicalTrials.gov · NCT05759793 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources